bluebird bio, Inc. (NASDAQ:BLUE) CEO Nick Leschly sold 5,435 shares of bluebird bio stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $173.38, for a total value of $942,320.30. Following the completion of the transaction, the chief executive officer now owns 171,009 shares in the company, valued at approximately $29,649,540.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Nick Leschly also recently made the following trade(s):

  • On Wednesday, December 13th, Nick Leschly sold 117,500 shares of bluebird bio stock. The shares were sold at an average price of $184.08, for a total value of $21,629,400.00.
  • On Wednesday, November 1st, Nick Leschly sold 2,127 shares of bluebird bio stock. The shares were sold at an average price of $145.17, for a total value of $308,776.59.
  • On Friday, October 20th, Nick Leschly sold 3,350 shares of bluebird bio stock. The shares were sold at an average price of $145.02, for a total value of $485,817.00.
  • On Monday, October 23rd, Nick Leschly sold 7,050 shares of bluebird bio stock. The shares were sold at an average price of $145.14, for a total value of $1,023,237.00.
  • On Tuesday, October 17th, Nick Leschly sold 10,823 shares of bluebird bio stock. The shares were sold at an average price of $145.05, for a total value of $1,569,876.15.

Shares of bluebird bio, Inc. (NASDAQ BLUE) opened at $171.65 on Friday. bluebird bio, Inc. has a 12 month low of $63.10 and a 12 month high of $222.03. The company has a market capitalization of $7,870.00, a PE ratio of -24.49 and a beta of 2.08.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). The firm had revenue of $7.71 million for the quarter, compared to analyst estimates of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The business’s revenue for the quarter was up 397.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($2.07) earnings per share. equities research analysts anticipate that bluebird bio, Inc. will post -6.72 EPS for the current fiscal year.

A number of research firms have issued reports on BLUE. Leerink Swann reiterated an “outperform” rating and issued a $120.00 target price on shares of bluebird bio in a research report on Saturday, September 30th. Oppenheimer reiterated a “hold” rating on shares of bluebird bio in a research report on Tuesday. CIBC began coverage on bluebird bio in a research report on Thursday, December 21st. They issued a “market perform” rating on the stock. Morgan Stanley cut bluebird bio from an “equal weight” rating to an “underweight” rating and set a $105.00 target price on the stock. in a research report on Monday, October 2nd. Finally, Maxim Group reiterated a “buy” rating and issued a $170.00 target price on shares of bluebird bio in a research report on Thursday, November 2nd. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have given a buy rating to the stock. bluebird bio has an average rating of “Hold” and an average price target of $157.45.

Several institutional investors have recently bought and sold shares of BLUE. QS Investors LLC lifted its stake in shares of bluebird bio by 70.7% in the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 500 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of bluebird bio by 454.2% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 813 shares during the period. Biondo Investment Advisors LLC acquired a new position in shares of bluebird bio in the third quarter worth approximately $203,000. SG Americas Securities LLC lifted its stake in shares of bluebird bio by 17.9% in the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 295 shares during the period. Finally, Fairfield Bush & CO. acquired a new position in shares of bluebird bio in the second quarter worth approximately $210,000.

ILLEGAL ACTIVITY NOTICE: “bluebird bio, Inc. (BLUE) CEO Sells $942,320.30 in Stock” was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/bluebird-bio-inc-blue-ceo-sells-942320-30-in-stock/1803877.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with Analyst Ratings Network's FREE daily email newsletter.